



# **PATIENT CENTRICITY in Medical Affairs:** Identifying and Overcoming Barriers

Presented by the MAPS Patient Centricity Focus Area Working Group

### **Presenters**



Betsy Williams, Ph.D.

Senior Director, Patient Centered Solutions IQVIA USA



Jessica Santos, Ph.D.

Global Head of Compliance, DPO Oracle Life Science UK



Rebecca Vermeulen

VP Global Patient Network, Product Dev Medical Affairs Genentech/Roche USA

### Conflict of Interest and Disclosures

- Betsy Williams is employed by IQVIA
- Jessica Santos is employed by Oracle
- Rebecca Vermeulen is employed by Genentech, a Member Company of Roche

The opinions expressed herein are the presenters' own and do not reflect the opinions or interest of the companies who employ them.

### **Educational Objectives**

#### This session will provide a learning opportunity for our audience by:

- Sharing insights from the recent MAPS Patient Centricity Survey on industry perspectives
- Providing guidance and potential solutions on addressing major barriers for Patient Centricity Initiatives identified through the survey

### MAPS conducted a survey to better understand Patient Centricity (PC) in practice, followed by individual interviews

#### Goal:

Gain a deeper understanding on how patient centricity lives in different organizations, including best practices, current trends, specifics about barriers, and opportunities to overcome those


#### Approach:

**Survey Medical Affairs professionals and industry** members November 2022 (n=133)

Direct outreach *≡*⊠ to MAPS members



LinkedIn



Follow up interviews with experienced Medical Affairs professionals March - May 2023 (n=11)



In-person and remote, single and panel interviews



### Perspective on the meaning of Patient Centricity in organizations varied widely



- What it is (Definition)
- Who is responsible
- What initiatives are in scope without overstepping boundaries
- What is its impact/return
- How does it transfer to day-to-day routines for individual roles




### Based on feedback from the survey, the FAWG developed a definition of Patient Centricity in Medical Affairs

#### 1. Received feedback on 2 current definitions for Patient Centricity



#### 2. Developed Definition for Patient Centricity



#### What is Patient Centricity in Medical Affairs?


Patient centricity in Medical Affairs puts the patient in the center of ethical considerations and decision making across the product development lifecycle.

It is prioritizing the patient and their support network to foster active engagement and transparent partnership and integrating their perspectives in Medical Affairs activities.

It supports the goals of optimizing outcomes and quality of life for patients, promotes accessibility and inclusion, improves patient experiences, and places patient needs at the forefront of healthcare innovation.

### Based on survey responses, compliance and financial constraints were identified as major barriers

#### % of responses (n=93) | Major barrier for Patient Centricity



### Interviewees provided potential solutions to overcoming compliance - increased education, collaboration, and advocacy

COMPLIANCE as major barrier for Patient Centricity Reasons **Initiatives Potential Solutions** 

Unclear boundaries of Patient Centricity vs advertisement

Risk averse company compliance guidance

Guidelines/policies lag global trends (e.g., patients increasingly using social media or YouTube)

Regional differences

Insufficient mutual understanding with compliance team

- Educate organization on compliance issues, show opportunities and boundaries, and processes
- Increased and earlier collaboration with compliance teams
- **Advocacy** for updating guidelines and policy


### Polling Question 1 — "Is compliance a partner?"

**Question:** Are you proactively reaching out to your compliance team when you plan patient centricity initiatives?


#### **Responses:**

- Yes I include my compliance team during the planning process
- Getting there I start out on my own but involve compliance later
- No I do not involve my compliance team in patient centricity initiatives
- I do not plan patient centricity initiatives

## Compliance is



### Some Compliance Considerations




### Privacy



GDPR, CPRA, HIPAA

Sensitive data / personal data / pseudonymised data / anonymised data

> Data **Controller** /Data **Processor** /Data **Subject**



More details: https://www.dlapiperdataprotection.com/#handbook/world-map-section

## Direct to Patient Engagement



Advertising?

**Communication?** 

**Participation?** 


**Advisory Board** 

**Social Media** 



### Let's talk about money \$€£





# Legal



Contract / Agreement / Consent

Liability

Indemnity

Confidentiality

Risk assessment



### **Ethics**



**Principles - Beneficence,** nonmaleficence, autonomy & justice

**Practitioner vs Subject** 

IRB (Independent Review Board) / EC (Ethics Committee)

**Risk vs Benefit to Patients** 

**Code of conduct / Guidance** 



Ref: https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html

# Underappreciation of the cost benefit of Patient Centricity initiatives and poor planning lead to financial constraints

FINANCIAL CONSTRAINTS

as major barrier for Patient Centricity Initiatives



Potential Solutions

Organizational priorities: Budgets purely based and prioritized on ROI

Poor planning: Initiative owners, mostly the executing function, do not account for PCIs in annual budgeting process. Ad-hoc budget unlikely

Patient Centricity not reflected in organizational goals

Digital initiatives are very expensive

Showcase competitive advantage to C-suite and

- **1 shareholders** to increase appreciation for potential cost benefit from including the patient
- 2 Focus on timely and proper budget planning

"Once it starts to become clear that the [organizations] who do this [patient centricity] well are becoming more successful, enrolling patients faster, getting drugs to the market faster, having better engagement....."
[Interview participant]

### Polling Question 2 – "Guesstimate"


**Question:** For a pre-phase 2 project, the cumulative impact of a patient engagement activity that avoids one protocol amendment and improves enrollment, adherence, and retention is an increase in net present value (NPV) of how much?

#### **Responses:**

- \$7.5 million USD
- \$22 million USD
- o \$45 million USD
- \$62 million USD


#### The Added Value When Patient Engagement is Done Right

#### Positive impacts felt across the full lifecycle of the medicine



#### Case Study: Partnerships with the SMA Patient Community

Ensured our strategy and programme addressed patient needs




SMA Europe:

"We are proud of our long-established partnership with Roche. Our close collaboration has ensured that the community's expectations and unmet needs are at the centre of decisionmaking."

#### To Summarize


- According to the MAPS Patient Centricity FAWG survey and additional interviews, compliance and financial considerations were the major barriers to implementing patient centricity initiatives in Medical Affairs.
- We developed a specific definition for Patient Centricity in Medical Affairs based on input from the survey
- Jessica provided considerations to keep in mind when working with your compliance team, including starting as early as possible and considering compliance as a partner
- Rebecca provided considerations for financial implications of both engaging and not engaging in patient centricity activities





# **Additional Information**


# Most of the 133 survey respondents are well experienced Medical Affairs professionals



### Most respondents had experience with PC, whereas MA often budgets and leads initiatives – but KPIs not systematically implemented


#### **Experience** with patient centricity initiatives

n=133




#### Role of MA in PC initiatives

n=92



#### **Organization implemented success** measurement for PC initiatives


n=96



### All 11 interviewees are well experienced Medical Affairs professionals, and half of them were from large pharma


#### Half of interviews were conducted with experts from large pharma

n=8



#### Most are Head or Vice president of Medical Affairs...

n=11



#### ... with many years of MA experience

n=11



### The need to shift the organizational mindset to truly live Patient Centricity was reported as one of the biggest challenges

#### Major barrier mentioned | n=20 (%)

